MedTrace Logo

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

NCT03005704 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-04-06

No results posted yet for this study

Summary

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

Conditions

  • Ticagrelor
  • Aspirin
  • Platelet Dysfunction Due to Drugs
  • Transfusion

Interventions

DRUG

Antiplatelet treatment

Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03005704 on ClinicalTrials.gov